299 related articles for article (PubMed ID: 34874743)
1. Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T; Jouni M; Kuo HH; Weddle CJ; Lyra-Leite D; Fonoudi H; Romero-Tejeda M; Gharib M; Javed H; Fajardo G; Ross CJD; Carleton BC; Bernstein D; Burridge PW
Circulation; 2022 Jan; 145(4):279-294. PubMed ID: 34874743
[TBL] [Abstract][Full Text] [Related]
2. Functional Validation of Doxorubicin-Induced Cardiotoxicity-Related Genes.
Fonoudi H; Jouni M; Cejas RB; Magdy T; Blancard M; Ge N; Shah DA; Lyra-Leite DM; Neupane A; Gharib M; Jiang Z; Sapkota Y; Burridge PW
JACC CardioOncol; 2024 Feb; 6(1):38-50. PubMed ID: 38510289
[TBL] [Abstract][Full Text] [Related]
3. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes.
Christidi E; Huang H; Shafaattalab S; Maillet A; Lin E; Huang K; Laksman Z; Davis MK; Tibbits GF; Brunham LR
Sci Rep; 2020 Jun; 10(1):10363. PubMed ID: 32587261
[TBL] [Abstract][Full Text] [Related]
4. RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy.
Magdy T; Jiang Z; Jouni M; Fonoudi H; Lyra-Leite D; Jung G; Romero-Tejeda M; Kuo HH; Fetterman KA; Gharib M; Burmeister BT; Zhao M; Sapkota Y; Ross CJ; Carleton BC; Bernstein D; Burridge PW
Cell Stem Cell; 2021 Dec; 28(12):2076-2089.e7. PubMed ID: 34525346
[TBL] [Abstract][Full Text] [Related]
5. The Role of RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 Single-nucleotide Polymorphisms in the Doxorubicin-induced Cardiotoxicity in Solid Childhood Tumors.
Gündüz A; Duman D; Başbinar Y; Taşdelen B; Küpeli S; Karpuz D
J Pediatr Hematol Oncol; 2024 Jan; 46(1):e65-e70. PubMed ID: 37828659
[TBL] [Abstract][Full Text] [Related]
6. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes.
Maillet A; Tan K; Chai X; Sadananda SN; Mehta A; Ooi J; Hayden MR; Pouladi MA; Ghosh S; Shim W; Brunham LR
Sci Rep; 2016 May; 6():25333. PubMed ID: 27142468
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide CRISPR/Cas9 screening in human iPS derived cardiomyocytes uncovers novel mediators of doxorubicin cardiotoxicity.
Sapp V; Aguirre A; Mainkar G; Ding J; Adler E; Liao R; Sharma S; Jain M
Sci Rep; 2021 Jul; 11(1):13866. PubMed ID: 34230586
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients.
Vargas-Neri JL; Carleton B; Ross CJ; Medeiros M; Castañeda-Hernández G; Clark P
Pharmacogenomics; 2022 Apr; 23(5):291-301. PubMed ID: 35147047
[No Abstract] [Full Text] [Related]
9. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
10. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Burridge PW; Li YF; Matsa E; Wu H; Ong SG; Sharma A; Holmström A; Chang AC; Coronado MJ; Ebert AD; Knowles JW; Telli ML; Witteles RM; Blau HM; Bernstein D; Altman RB; Wu JC
Nat Med; 2016 May; 22(5):547-56. PubMed ID: 27089514
[TBL] [Abstract][Full Text] [Related]
11. Use of Human Pluripotent Stem Cell Derived-Cardiomyocytes to Study Drug-Induced Cardiotoxicity.
Maillet A; Tan KP; Brunham LR
Curr Protoc Toxicol; 2017 Aug; 73():22.5.1-22.5.22. PubMed ID: 28777443
[TBL] [Abstract][Full Text] [Related]
12. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
13. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
14. RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes.
Huang H; Christidi E; Shafaattalab S; Davis MK; Tibbits GF; Brunham LR
Stem Cell Reports; 2022 Apr; 17(4):756-765. PubMed ID: 35364012
[TBL] [Abstract][Full Text] [Related]
15. Exosomal LncRNA-NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p.
Zhuang L; Xia W; Chen D; Ye Y; Hu T; Li S; Hou M
J Nanobiotechnology; 2020 Oct; 18(1):157. PubMed ID: 33129330
[TBL] [Abstract][Full Text] [Related]
16. LncRNA FOXC2-AS1 protects cardiomyocytes from doxorubicin-induced cardiotoxicity through activation of WNT1-inducible signaling pathway protein-1.
Zhang S; Yuan Y; Zhang Z; Guo J; Li J; Zhao K; Qin Y; Qiu C
Biosci Biotechnol Biochem; 2019 Apr; 83(4):653-658. PubMed ID: 30558506
[TBL] [Abstract][Full Text] [Related]
17. Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors.
Chaix MA; Parmar N; Kinnear C; Lafreniere-Roula M; Akinrinade O; Yao R; Miron A; Lam E; Meng G; Christie A; Manickaraj AK; Marjerrison S; Dillenburg R; Bassal M; Lougheed J; Zelcer S; Rosenberg H; Hodgson D; Sender L; Kantor P; Manlhiot C; Ellis J; Mertens L; Nathan PC; Mital S
JACC CardioOncol; 2020 Dec; 2(5):690-706. PubMed ID: 34396283
[TBL] [Abstract][Full Text] [Related]
18. Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression.
Gupta SK; Garg A; Bär C; Chatterjee S; Foinquinos A; Milting H; Streckfuß-Bömeke K; Fiedler J; Thum T
Circ Res; 2018 Jan; 122(2):246-254. PubMed ID: 29133306
[TBL] [Abstract][Full Text] [Related]
19. Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.
Magdy T; Burridge PW
Pharmacogenomics; 2021 Jan; 22(1):41-54. PubMed ID: 33448871
[TBL] [Abstract][Full Text] [Related]
20. Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity.
Siemens A; Rassekh SR; Ross CJD; Carleton BC
Ther Drug Monit; 2023 Jun; 45(3):337-344. PubMed ID: 36728273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
